DNA Methylation Profiling across the Spectrum of HPV-Associated Anal Squamous Neoplasia

Jonathan M. Hernandez1, Erin M. Siegel2, Bridget Riggs2, Steven Eschrich3, Abul Elahi1, Xiaotao Qu3, Abidemi Ajidahun1, Anders Berglund3, Domenico Coppola4, William M. Grady5,6, Anna R. Giuliano2, David Shibata1*

Background: Changes in host tumor genome DNA methylation patterns are among the molecular alterations associated with HPV-related carcinogenesis. However, there is little known about the epigenetic changes associated specifically with the development of anal squamous cell cancer (SCC). We sought to characterize broad methylation profiles across the spectrum of anal squamous neoplasia.

Methodology/Principal Findings: Twenty-nine formalin-fixed paraffin embedded samples from 24 patients were evaluated and included adjacent histologically normal anal mucosa (NM; n = 3), SCC-in situ (SCC-IS; n = 11) and invasive SCC (n = 15). Thirteen women and 11 men with a median age of 44 years (range 26–81) were included in the study. Using the SFP10 LIPA HPV-typing system, HPV was detected in at least one tissue from all patients with 93% (27/29) being positive for high-risk HPV types and 14 (93%) of 15 invasive SCC tissues testing positive for HPV 16. Bisulfite-modified DNA was interrogated for methylation at 1,505 CpG loci representing 807 genes using the Illumina GoldenGate Methylation Array. When comparing the progression from normal anal mucosa and SCC-IS to invasive SCC, 22 CpG loci representing 20 genes demonstrated significant differential methylation (p < 0.01). The majority of differentially methylated gene targets occurred at or close to specific chromosomal locations such as previously described HPV methylation “hotspots” and viral integration sites.

Conclusions: We have identified a panel of differentially methylated CpG loci across the spectrum of HPV-associated squamous neoplasia of the anus. To our knowledge, this is the first reported application of large-scale high throughput methylation analysis for the study of anal neoplasia. Our findings support further investigations into the role of host-genome methylation in HPV-associated anal carcinogenesis with implications towards enhanced diagnosis and screening strategies.

Abstract

Introduction

Anal squamous cell cancers (SCC) account for 4% of all lower gastrointestinal tract malignancies in the United States with an estimated 6,230 new cases and 780 deaths expected in 2012 [1]. The incidence of anal cancer continues to rise steadily, with an average increase of 2.4% per year reported between 1992 and 2009 [2,3]. Infection with human papillomavirus (HPV) has been demonstrated to be the primary causative agent in the development of SCC of the anogenital tract, including cancers of the cervix, vulva, vagina and anus [4]. Although infection with HPV is a common event, the subsequent development of cancer is rare, suggesting that additional molecular events are required for malignant transformation [5].

Anal intraepithelial neoplasia (AIN) is the precursor lesion of invasive anal SCC. It is generally thought that high grade AIN (HGAIN) or carcinoma in situ, but not low grade lesions, are at risk of malignant progression to invasive anal SCC. It is estimated that the risk of malignant progression of HGAIN is approximately 10% but may be higher in immunocompromised individuals [6]. Consequently, the optimal method for screening and managing patients with HGAIN (e.g. prophylactic treatment vs. observation) remains somewhat controversial [7,8]. Molecular biomarkers of anal neoplasia have the potential to more accurately risk stratify HGAINs and also may improve the low sensitivity of HGAIN diagnosis found with anal PAP smears, thus reducing the need for costly invasive biopsies [9].

Citation: Hernandez JM, Siegel EM, Riggs B, Eschrich S, Elahi A, et al. (2012) DNA Methylation Profiling across the Spectrum of HPV-Associated Anal Squamous Neoplasia. PLoS ONE 7(11): e50533. doi:10.1371/journal.pone.0050533

Editor: Sunil K Ahuja, South Texas Veterans Health Care System and University Health Science Center San Antonio, United States of America

Received April 12, 2011; Accepted September 27, 2012; Published November 30, 2012

Copyright: © 2012 Hernandez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors have no funding or support to report.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: david.shibata@moffitt.org

† These authors contributed equally to this work.
It is well recognized that genetic mutations occur in cancer cells and that these exert disease-associated changes in gene expression and/or function. Very little is known about the specific genetic events that drive anal carcinogenesis; although it has been reported that alterations in TP53, DCC, APC and FHIT may be contributing factors [10,11]. Cancer cells also exhibit aberrant epigenetic alterations which appear to play a prominent role in cancer development. DNA methylation is a key aberrant epigenetic event that has been documented in virtually every tumor type studied and is amongst the earliest disease-associated changes observed during tumorigenesis [12]. HPV may influence the host transcriptome via a number of epigenetic mechanisms [5,13] including HPV E7 oncoprotein-mediated alterations in the activity of DNA methyltransferases (DNMTs) [14,15], histone deacetylases (HDACs), and pCAF acetyltransferase [14,16].

Despite the likely importance of aberrant DNA methylation in the pathogenesis of anal SCC, there has only been one report investigating methylation in anal cancer. Zhang et al. evaluated the methylation status of 11 candidate genes identified from studies of other HPV-associated malignancies [9]. They reported higher methylation in HGAIN and anal cancer for two genes compared to normal mucosa or low-grade lesions suggesting a role for DNA methylation in anal carcinogenesis. Additional epigenetic targets unique to anal cancer may be uncovered by a more comprehensive high-throughput methylation array approach. However, due in part to the limited quantity and quality of anal cancer tissue specimens, broad scale genomic techniques have not been widely applied to this disease site. The successfully met objectives of this study were first, to demonstrate the feasibility of investigating DNA methylation in anal cancer utilizing methylation array technology and second, to identify CpG loci that were differentially methylated in invasive SCC compared to pre-invasive and/or normal mucosa.

Materials and Methods

Ethics Statement

Our study was approved by the Institutional Review Board at the University of South Florida as exempt and not requiring informed consent from study subjects. Data were collected and appropriately de-identified prior to analysis.

Case Identification and Tissue Collection

The records of all patients treated at the H. Lee Moffitt Cancer Center and Research Institute from 2000–2008 with the diagnosis of anal SCC or SCC in situ (SCC-IS) were reviewed. Patients with a pathological diagnosis of SCC or SCC-IS of the anus and sufficient formalin-fixed paraffin-embedded (FFPE) tissue for analysis were identified. Pertinent clinical data were collected retrospectively utilizing our institutional electronic medical record system. We identified 24 patients treated at the Moffitt Cancer Center that met our inclusion criteria. Median age for the 24 patients (13 females and 11 males) in the study population was 44 years (range 26–81). Five patients were immunocompromised secondary to HIV (n = 3) or immunosuppressive medications given for organ transplantation (n = 2).

To ensure the accuracy of diagnosis, tissue samples were reviewed and regions of histologically normal mucosa, SCC-IS, and SCC were marked by a dedicated gastrointestinal pathologist (DC). FFPE tissues were subsequently cut (15 μm thick) and meticulously macrodissected to reduce cross contamination. Prior to the macrodissection of each case, gloves and instruments were changed and the workspace was disinfected. Of note, for the purposes of this study, SCC-IS is considered equivalent to AIN III and HGAIN.

HPV Genotyping

DNA was extracted from FFPE tissues using QIAamp DNA FFPE Tissue Kit (Qiagen Inc, Valencia, CA). HPV genotyping was performed using the INNO-LiPA HPV Genotyping Extra kit (Innogenetics, Belgium). In brief, 100 ng of DNA was utilized for PCR amplification of a short fragment (65-bp) of the HPV L1 region with biotinylated primers (SPF) using the MJ PTC-200 DNA engine thermocycler. PCR products were hybridized to the AutoBlot 3000H 20 Strip, a probe-specific nitrocellulose test strip, placed on an adhesive LiPA-Scan Reading template and analyzed using the LiRAS for LiPA HPV v2.01 software (Innogenetics, Belgium). All assays included the amplification of a 270 bp fragment of HLA-DPB1 as a positive control for human DNA. All PCR runs met quality control standards, with all samples positive for internal positive controls and negative controls negative for each run. This system detects 28 HPV types (HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70, 73, and 82). High-risk HPV types were defined as the 12 high-risk types classified as group 1 carcinogens (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) [17].

Methylation Array

Genomic DNA (500 ng) was sodium bisulfite-modified using the EZ DNA Methylation kit (Zymo Research, Orange, CA) following the manufacturer’s instructions. DNA methylation was measured using the Illumina GoldenGate methylation assay with the Cancer Panel 1 probes (Illumina, San Diego, CA) following standard protocols [18]. This bead array platform interrogated 1505 CpG loci that represent 807 cancer-related genes. In brief, following methylation-specific hybridization, allele specific oligonucleotides were extended and ligated to a locus-specific oligonucleotide (LSO), which served as the template for fluorescently labeled universal primers that amplify either unmethylated (U) or methylated (M) templates. Labeled DNA contained a unique IllumiCode address for hybridization to its complement bead type (~30 replicates per CpG site) on a Sentrix Array Matrix (SAM) plate. At each CpG site, U and M fluorescent intensities were measured, averaged across replicate beads, and compared to a panel of negative controls using the Illumina’s BeadStudio

---

**Table 1. Primers for Bisulfite Sequencing,***

| Gene   | Forward Primer | Reverse Primer | Annealing Temp | MgCl2 | Amplicon size (bp) |
|--------|----------------|----------------|----------------|-------|--------------------|
| HOX5   | TTA TTA GGA TGT ATT AAT TGT TAG GT | CAA AAT TCA AAA CTA CTA ACA AAA C | 48.2  | 2.5   | 192                |
| TGFß3  | GAT TGA GGT TTG GTA AGA AGG TGT A | ACT AAA AAT CAA AAC CCA ACA AAA C | 56.5  | 2.5   | 167                |
| KRT1   | TAG AGT AGG AGA TAG ATA TTA G | TCC AAT ATA AAA CTT AAA TCA CC | 48.2  | 2.75  | 176                |

*doi:10.1371/journal.pone.0050533.t001*
Methylation Module v3.2. Probes that were significantly different from negative controls were included in the analysis.

Bisulfite Sequencing

Primer design and amplification of target CpG site. Primer sets targeting HOXA5, TGFβ3, and KRT1 genes were designed with MethPrimer software [19] or derived from the published literature (Table 1). The primers specifically amplified the CpG sites measured in the Illumina GoldenGate assay. Using 2 μl of bisulfite-converted DNA as PCR template, a 50 μl reaction containing 0.02 μM of each primer, 0.2 mM dNTP, 1 unit of HotStarTaq Plus polymerase and varying amounts of magnesium was performed. Initial denaturation was at 95°C for 15 min, followed by 40 cycles of 94°C for 1 min, 48.2°C–56.5°C annealing for 1 min and 72°C for 1 min; and a final extension cycle of 72°C for 10 min. PCR products were viewed with a 1.5% agarose gel stained with ethidium bromide. Target amplicons were gel-extracted and purified using the QIAquick Gel Extraction Kit (Qiagen Inc., Valencia, CA) according to the manufacturer’s instructions.

Figure 1. Gender Heatmap of X-linked CpG Loci. DNA methylation is involved in the transcriptional activation of genes on one of the two X chromosomes in female somatic cells. In general, male and female cases clustered together with methylation levels of the majority of X-linked genes correlating well with the gender of the tissue source (i.e. little-to-no methylation in male samples and hemi-methylation in female samples). Sample gender is represented above the heatmap (pink = female, blue = male). Methylation is represented by the beta value, or percent of total signal with green representing low methylation and red representing hemi-methylation. 51 of 84 loci within X-linked genes were differentially methylated (p<0.05) between males and females.

doi:10.1371/journal.pone.0050533.g001

Methylation Module v3.2. Probes that were significantly different from negative controls were included in the analysis.
Methylation data were pre-processed by setting non-detected probes as N/A (Not Applicable) for samples in which the detection p value for the probe was >0.05. Chip-wide controls and Multi-Dimensional Scaling plots were used to visualize data quality. Methylation data were analyzed using the R statistical software package and Bioconductor packages. Internal functional validation of the assay was performed by unsupervised clustering to confirm separation by gender due to the presence of X-linked CpG sites on the array (Figure 1) [18]. Analysis of X-linked genes with respect to gender was performed using the Mann-Whitney non-parametric test with p<0.05 as the threshold for significance. Clustering was performed using non-centered correlation as the similarity metric within R. X-linked methylation probes were then discarded prior to further analysis.

The number of paired, matched tissues was small; therefore, we examined the three groups of tissues in a pooled fashion to identify targets with differential methylation in pre-invasive (normal and SCC-IS) vs. invasive cancer samples. Due to non-normal distribution of beta ratios, we applied a Mann-Whitney non-parametric test with p<0.05 as the threshold to partially correct for multiple testing problems.

Additional analysis was performed using a Kruskal-Wallis non-parametric test to accommodate variables with three levels (Normal, SCC-IS and Invasive).

Results

HPV Genotyping

HPV genotyping was performed on adjacent histologically normal anal mucosa (n = 3), SCC-IS (n = 11), and SCC (n = 15) tissues. HPV viral DNA was detected in all tissues, with 38 total infections detected (33 high-risk and 5 low-risk types, Table 2). High-risk HPV types were detected in 93% (27/29) of tissues; 3 patients with SCC-IS were positive for low-risk HPV 6. HPV 16 was the most common infection, being detected in 76% (22/29) tissue samples overall and in 87% of SCCs. It was most often detected as a single infection (59%, 17/29 tissue sections). Two SCCs were positive for HPV 52; whereas HPV 18 was only detected in one SCC-IS. Infection with multiple HPV types was detected in 7 (29%) of 24 patients, of which two were HIV positive. The detection of low-risk and high-risk types occurred concurrently in 3 out of the 5 low-risk infections detected; specifically, two SCC tissues had co-infection with HPV 11 and 16. Of the SCC-IS tissues where HPV 6 was detected, only one had a concurrent high-risk type detected (HPV 52). No correlation between multiple infections and histological diagnosis (normal mucosa, SCC-IS, SCC) or immunocompetency was identified.

Quality Control Analysis of GoldenGate DNA Methylation Data

The GoldenGate array contains standard control probes that assess several parameters including 1) Allele specific extension, 2) Bisulfite Conversion, 3) Extension Gap, 4) First hybridization, 5) Gender, 6) Negative Control, 7) PCR Contamination, and 8) Second Hybridization [18]. All cases used for this study were reviewed and passed these quality control measures. Figure 1 presents the quality control analysis of the methylation probes by gender to confirm separation due to the presence of X-linked CpG sites on the array [18]. In an unsupervised cluster analysis of X-linked CpG sites, a distinct separation of patients by gender was observed with 51 of 84 (61%) X-linked genes found to be differentially methylated (p<0.05) between specimens derived from male and female patients. These analyses support the internal validity of our methylation data.
Differential Methylation in Invasive SCC vs. Pre-invasive Anal Tissue

To optimize the numbers of cases per comparison group, methylation profiles were compared between pre-invasive anal tissue (normal and SCC-IS) and invasive SCC specimens using the Mann-Whitney test. A total of 22 CpG loci corresponding to 20 genes was noted to have significant (p < 0.01) differential methylation between the two groups (Table 3). Of these, all but 2 CpG loci demonstrated increased methylation in invasive SCC compared to pre-invasive tissues. Table 1 provides detailed annotation for genes containing differentially methylated CpG loci.

There were three distinct patterns of methylation observed in the differentially methylated CpG panel (Figure 2): 1) Loci with low methylation levels (median beta value = 0.3) in all tissue types (e.g. ID1, KDR, TNFRSF10B, and SEMA3B) but with a statistically significant difference between non-invasive and invasive tissues; 2) loci with high methylation levels (median beta ≥ 0.3) in all tissue types (e.g. GABRA5, BCL2A1, CCL3, DIO3, FRK, KRT1, KRT5, P2RX7, PRSS8, and TGF3) but with a statistically significant difference between non-invasive and invasive tissues; and 3) loci with little to no methylation in non-invasive tissues (beta values < 0.3) with a significant increase above the threshold into invasive tissues.

### Table 3. Genes with Differentially Methylated CpG Loci in the Progression of Anal Neoplasia.

| Symbol | Product | Annotation | CpG Number* | P-value |
|--------|---------|------------|-------------|---------|
| **Growth Regulation and Cell Cycle Control** |
| TGFB3 | Transforming growth factor, beta 3 | Controls proliferation and differentiation | cg17928876 | 0.0012; 0.0063 |
| FRK | Fyn-related kinase | SRC kinase family with epithelial tissue-specific expression | cg26557270 | 0.0054; 0.0247 |
| PADI4 | Peptidyl arginine deiminase, type IV | Post-translational modification (arginine methylation and citrullination) of histones | cg19159961 | 0.0030; 0.0155 |
| ID1 | Inhibitor of DNA binding 1 isoform a | Helix-loop-helix protein | cg09569033 | 0.0071; 0.0228 |
| **Differentiation** |
| S100A2 | S100 calcium binding protein A2 | Small, acidic Ca(2+)-binding proteins in nucleus | cg09232826; cg21074565 | 0.0015; 0.0040; 0.0325 |
| KRT1 | Keratin 1 | Differentiation-dependent keratin | cg06030058 | 0.0015; 0.0071 |
| KRT5 | Keratin 5 | Primary keratin | cg04254916 | 0.0033; 0.0154 |
| PRSS8 | Prostasin pre-protein | Trypsinogen; serine proteases | cg27436259 | 0.0022; 0.0116 |
| **Angiogenesis** |
| ELT1 | Fms-related tyrosine kinase 1 | VEGF receptor tyrosine kinase (also VEGFR1) | cg1787743 | 0.0020; 0.0041 |
| KDR | Kinase insert domain receptor | VEGF Type III receptor tyrosine kinase (also VEGFR2) | cg04695981 | 0.0044; 0.0197 |
| **Apoptosis** |
| DAPK1 | Death-associated protein kinase 1 | Calmodulin-dependent serine-threonine kinase | cg01984172 | 0.0021; 0.0106 |
| HOXA5 | Homeobox A5 | DNA-binding transcription factor | cg27409178 | 0.0037; 0.0133 |
| TNFRSF10B | Tumor necrosis factor receptor superfamily, 10b | Death domain associated receptor | cg07508317 | 0.0026; 0.0112 |
| BCL2A1 | BCL2-related protein A1 | Reduces pro-apoptotic cytochrome C release; blocks caspase activation. | cg27177709 | 0.0061; 0.0262 |
| SEMA3B | Semaphorin 3B isoform 1 | Extracellular secreted protein important in axonal guidance; induces apoptosis | cg12999941 | 0.0083; 0.0283 |
| **Other Processes** |
| CCL3 | Chemokine (C-C motif) ligand 3 | Macrophage inflammatory protein-1 | cg05481196 | 0.0096; 0.0374 |
| P2RX7 | Purinergic receptor P2X7 isoform b | Cell surface ATP receptor; ligand-gated ion channel | cg08688169 | 0.0096; 0.0156 |
| CD9 | CD9 antigen | Cell surface tetraspanin (TM4SF) glycoprotein | cg19415774 | 0.0071; 0.0228 |
| DIO3 | Deiodinase, iodothyronine, III | Selenoenzyme | cg18191511 | 0.0074; 0.0133 |
| GABRA5 | Gamma-aminobutyric acid A receptor, alpha 5 | Heteromeric pentameric ligand-gated ion channels | cg02225257; cg20051555 | 0.0030; 0.0044; 0.0112; 0.0044 |

*CpG locus label within the GoldenGate methylation array.

1 Mann-Whitney test for methylation differences between two groups (pre-invasive vs. invasive SCC) using a conservative threshold to partially correct for multiple testing problems (p < 0.01).

2 Kruskal-Wallis non-parametric test performed to test three levels (Normal, SCC-IS and Invasive).

doi:10.1371/journal.pone.0050533.t003
high methylation levels (beta ≥ 0.3) in invasive SCC (e.g. CD9, DAPK1, FLT1, HOXA5, and PADI4). For S100A2, one CpG site demonstrated low methylation levels in all tissues (median beta value < 0.3) while the other was consistent with pattern 3; however, the general trend was suggestive of a low to high methylation pattern across both sites within this gene.

Although the number of samples in each group was relatively small, and particularly, in the normal tissue group, we performed an exploratory analysis to identify targets with differential methylation across all three groups (normal, SCC-IS and SCC). Using a Kruskal-Wallis non-parametric test and p-value < 0.01, 7 probes had differential methylation across the 3 groups, four of which (S100A2, FLT1, TGFB3 and KRT1) were identified in our binary analysis (Table 3 and Figure 2) and three were not (BMP4, EV12A, and ILIRN). In fact, the top 20 significant and near significant (p < 0.02) differentially methylated loci from the Kruskal-Wallis analysis and the top 20 significant (p < 0.01) loci from the Mann-Whitney analysis were highly similar with 13 CpG sites in common.

Measurement of Methylated Targets by Bisulfite Sequencing

Given the scarcity of these specimens, a confirmatory measurement of methylation using conventional bisulfite sequencing was performed in a total of 9 anal tissues (8 SCC and 1 SCC-IS) for which there was sufficient remaining tissue and/or genomic DNA. We selected 3 genes for the determination of methylation status by bisulfite sequencing; TGFβ3 and KRT1 had high methylation in all tissue types while HOXA5 demonstrated a progression of methylation from low to high levels across tissues. Within this study, the median beta values for CpG sites within TGFβ3, KRT1 and HOXA5 genes were 0.86, 0.86 and 0.77, respectively. Within the set of 9 patients, the average methylation levels at the CpG site of interest, as determined by bisulfite sequencing, for TGFβ3, KRT1 and HOXA5 were very similar to the corresponding average array beta values (63% vs. 69%; 68% vs. 76% and 63% vs. 63%, respectively). On an individual tissue specimen level, we demonstrated evidence of methylation (median beta value of ≥ 0.3) at the CpG site of interest in ≥ 30% of corresponding clones by bisulfite sequencing at concordance rates of 88% (8 of 9 clones) for TGFβ3, 75% (6/8) for HOXA5 and 100% (9/9) for KRT1. In all cases of non-concordance, a low array beta value was associated with a higher percentage of methylated clones by sequencing. Our findings confirm previous reports of high concordance between GoldenGate methylation array technology and conventional methylation assays [20,21].

Table 4. Chromosomal Mapping of Genes with Differentially Methylated CpG Loci.

| Gene Symbol | Chromosomal Location | Relation to HPV or hotspots |
|-------------|----------------------|----------------------------|
| TGFβ3       | 14q24.3              | HPV integration site       |
| GABRA5      | 15q12                | HPV integration site       |
| FRK         | 6q22.1               | HPV integration site       |
| CCL3        | 17q12                | HPV integration site       |
| KDR         | 4q12                 | HPV integration site       |
| BCL2A1      | 15q25.1              | Close to 15q25.3 HPV integration site |
| HOXA5       | 7p15.2               | HPV16 and 18 hypermethylation hotspot |
| DAPK1       | 9q21.33              | Close to 9q21.31 HPV18 hypermethylation hotspot |
| DIO3        | 14q32.31             | Close to 14q32.33 HPV 16 and 18 hypermethylation hotspot |
| P2RX7       | 12q24.31             | Close to 12q24.33 HPV 16 and 18 hypermethylation hotspot |
| S100A2      | 1q21.3               | Close to 1q21.1 HPV16 and 18 hypermethylation hotspot |
| KRT1        | 12q13.3              | Potential novel hypermethylation hotspot with KRT5 and CD9 |
| KRT5        | 12q13.3              | Potential novel hypermethylation hotspot with KRT1 and CD9 |
| CD9         | 12q13.3              | Potential novel hypermethylation hotspot with KRT1 and KRT5 |
| PRSS8       | 16p11.2              | Telomeric region           |
| ID1         | 20q11.2              | Telomeric region           |
| FLT1        | 13q12.2–12.3         | Telomeric region           |
| TNFRSF10B   | 8p21.3               | No associations            |
| SEMA3B      | 3p21.31              | No associations            |
| PADI4       | 1p36.13              | No associations            |

doi:10.1371/journal.pone.0050533.t004

Figure 2. Boxplot Representations of Selected Differentially Methylated CpG Loci. Boxplots illustrating methylation levels of selected significant differentially methylated CpG sites (Mann-Whitney p < 0.01) across histologic subtypes (normal and SCC-IS vs. invasive CC). Three patterns are identified: A: Loci with low methylation levels (median beta value < 0.3) across all tissues. B: Loci with high methylation levels (median beta value ≥ 0.3) across all tissues. C: Loci demonstrating little to no methylation in non-invasive tissues with significant levels of methylation in invasive SCC. doi:10.1371/journal.pone.0050533.g002
identified; however, HPV 18, 32, 39 and 52 were also observed. The HPV prevalence and type distribution are similar to previous reports in anal cancer [22–26]. In the current investigation, we utilized an FFPE-tissue compatible methylation array to evaluate the methylation status of 1,505 CpG loci representing 807 genes. We identified a panel of 20 CpG loci representing 19 genes with increased methylation in the progression from pre-invasive normal and SCC-IS tissues to invasive anal SCC. Of these CpG loci, 6 had low methylation levels in normal and pre-invasive tissues but were hypermethylated in invasive SCC. From a biological standpoint, this panel of CpG sites may represent biomarkers of anal neoplastic progression from non-invasive to invasive anal neoplasia and may reflect carcinogenesis-related epigenetic alterations with a transition from an unmethylated to methylated state.

We identified a panel of CpG loci that were differentially methylated in HPV-associated anal SCC (Table 3 and Table S1). These epigenetic events occurred in genes encoding proteins that play a role in growth regulation/cell cycle control (e.g. TGF-B3[27–29], FRK[30–32], PADI4[33–36], and ID[37–41]) and critical regulation of apoptosis (e.g. TNFRSF10B[42–47], DAPK1[48–50], HOXA5 [51–54], BCL2A1[55–59], and SEMA3B[60–62]). CpG loci that were shown to have high methylation levels across the spectrum of anal tissues but with a significant difference between non-invasive tissues and invasive SCC may be markers of early epigenetic alterations in HPV-induced carcinogenesis. For example, methylation of CpG loci in two keratin genes, KRT1 and KRT5, the products of which contribute to the differentiation of squamous epithelium, may be early biomarkers of HPV-associated carcinogenesis[63–65]. The HPV oncogenes E6 and E7 primarily target p53 and Rb, respectively, for degradation [66]. Interestingly, methylation levels of several CpG loci occurred within genes that either interact with or are part of the p53 or Rb pathways, including PADI4 [33,35], HOXA5 [67], FRK [32], and DAPK1 [50] (Table S1). Several differentially methylated loci identified in this study appear within genes that may be potential novel targets in the setting of cancer, such as FRK, BCL2A1, GABRA5, DIO3, P2RX7, CCL5 and ID. Overall, there appears to be a clustering of methylation in CpG sites across genes with similar functions within anal SCC and these epigenetic differences may have potential utility as biomarkers of HPV-associated carcinogenesis (Table S1) [68–93].

Zhang et al. evaluated the methylation status of 11 candidate genes (DAPK1, IGFB4, MLH1, HIC1, RARB, p14, TERT, MGMT, RASSF1, APC, and CDKN2A) in a set of 172 anal biopsies, which is the only published analysis of DNA methylation in anal cancer [9]. They reported an increased frequency of DAPK1 and IGFB4 methylation during the progression from normal mucosa to SCC-IS to invasive SCC. In our study, we have indeed confirmed that CpG loci within DAPK1 were among the most significantly methylated sites with increasing methylation across the spectrum of anal carcinogenesis. However, neither of the IGFB4 probes demonstrated significant differential methylation in our study (p=0.0297 and 0.0522 respectively by Mann-Whitney, data not shown). While data are limited in anal cancer, there is evidence for aberrant DNA methylation in HPV-associated cervical cancer [5,9,94]. Of the significant differentially methylated sites identified in our anal cancer study, DAPK1 is the only methylation target that has been similarly shown to be methylated in invasive cervical SCC (53%) and high-grade pre-invasive lesions (52%), with reduced methylation in normal and low-grade lesions [48,49,52–53]. These data support a possible role for the epigenetic alteration of DAPK1 in HPV-associated carcinogenesis.
which in turn may be a consequence of high risk HPV infection. With the application of broad high-throughput methylation profiling, we have generated a candidate list of progressively methylated CpG loci across the spectrum of anal squamous neoplasia, including sites within genes previously unassociated with anal SCC. Despite the small numbers of patients evaluated in this study, our findings are in agreement with what is known about the impact of HPV on epigenetic profiles including increased methylation at or close to specific chromosomal locations including previously described HPV methylation “hotspots” and viral integration sites. Our work represents an important initial step in understanding the epigenetic events associated with anal carcinogenesis. A critical translational step would be to apply broad methylation assays to identify a relevant panel of methylation biomarkers that could not only refine the diagnosis of HGAIN or SCC-IS but also serve as an indicator for increased risk of subsequent malignant transformation to invasive SCC.

Molecular guidance ultimately may reduce the burden of potentially unnecessary screening, biopsy and treatment procedures. Further evaluation of methylation events in anal squamous neoplasia is clearly warranted in larger patient populations and may contribute not only to a better understanding of anal carcinogenesis, but also to the development of novel biomarkers that may ultimately impact on enhanced diagnosis, screening and prevention.

Supporting Information

Figure S1  Boxplot Representations of All Differentially Methylated Loci. Boxplots illustrating methylation levels of 22 significant differentially methylated CpG sites representing 20 genes (Mann-Whitney p<0.01) across histologic subtypes (normal and SCC-IS vs. invasive CC). Three patterns are identified: A: Loci with low methylation levels (median beta value <0.3) across all tissues. B: Loci with high methylation levels (median beta value ≥0.3) across all tissues. The two CpG sites within the GaBRA5 gene demonstrated reduced methylation with neoplastic progression C: Loci demonstrating little to no methylation in non-invasive tissues with significant levels of methylation in invasive SCC. (TIF)

Table S1 Genes with Differentially Methylated CpG Loci in the Progression of Anal Neoplasia with Full Annotation. (DOC)

Acknowledgments

The authors would like to express their gratitude to Cassie Sather for her technical contributions and Suellen Sachariat for her assistance with manuscript preparation.

Author Contributions

Conceived and designed the experiments: EMS DS. Performed the experiments: JMH BR AE AA DC. Analyzed the data: EMS SE XQ AB DSB. Contributed reagents/materials/analysis tools: EMS DC WMG ARG DS. Wrote the paper: JMH EMS DS.

References

1. American Cancer Society (2012) Cancer Facts & Figures 2012. Atlanta, Ga.
2. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, et al. (2012) SEER Cancer Statistics Review, 1975-2009 (2009 Virtual Populations). National Cancer Institute. Bethesda, MD.
3. Eng C (2006) Anal cancer: current and future methodology. Cancer Invest 24: 533–544.
4. International Agency for Research on Cancer (2007) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 80 Human papillomaviruses; WHO and IARC, editors. Lyon, France. 1–636 p.
5. Whiteside MA, Siegel EM, Unger ER (2008) Human papillomavirus and molecular considerations for cancer risk. Cancer 113: 2981–2994.
6. Scholefield JH, Harris D, Radicliffe A (2011) Guidelines for management of anal intraepithelial neoplasia. Colorectal Dis 13 Suppl 1: 3–10.
7. Darragh TM, Winkler B (2011) Anal cancer and cervical cancer screening: key differences. Cancer Cytopathol 119: 5–19.
8. Grulich AE, Jin F, Conway EL, Stein AN, Hocking J (2010) Cancers attributable to human papillomavirus infection. Sex Health 7: 244–252.
9. Zhang J, Martins CR, Funder BZ, Roemer KL, Kincaid EA, et al. (2005) DNA methylation in anal intraepithelial lesions and anal squamous cell carcinoma. Clin Cancer Res 11: 6544–6549.
10. Gervaz P, Malhrooser D, Wolff BG, Anderson SA, Cunningham J, et al. (2004) Molecular biology of squamous cell carcinoma of the anus: a comparison of HIV-positive and HIV-negative patients. J Gastrointest Surg 8: 1024–1030; discussion 1031.
11. Zucchin C, Concric D, Martin T, Morelli C, Salfi N, et al. (2007) FHIT oncopressor gene expression profile in human anal cancers. Int J Biol Markers 22: 39–42.
12. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415–428.
13. Turan T, Kalantari M, Gallego-Macias IE, Cuble HA, Caschieri K, et al. (2006) Methylation of the human papillomavirus-18 L1 gene: a biomarker of neoplastic progression? Virology 349: 175–183.
14. Burgers WA, Blanchon I, Pradhan S, de Launoit Y, Kouzarides T, et al. (2007) Viral oncoproteins target the DNA methyltransferases. Oncogene 26: 1635–1655.
15. Leonard S, Lin Z, Zhou L, Chudin E, Garcia EW, et al. (2006) High-throughput DNA methylation profiling using universal bead arrays. Genome Res 16: 383–393.
16. Zhang J, Martins CR, Funder BZ, Roemer KL, Kincaid EA, et al. (2005) DNA methylation in anal intraepithelial lesions and anal squamous cell carcinoma. Clin Cancer Res 11: 6544–6549.

17. Schiffman M, Clifford G, Buonaguro FM (2009) Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiologic study at the border. Infect Agent Cancer 4: 8.
18. Bishova M, Liu Z, Zhou L, Chudin E, Garcia EW, et al. (2006) High-throughput DNA methylation profiling using universal bead arrays. Genome Res 16: 383–393.
19. Li LC, Daihya R (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427–1431.
20. McDonald FE, Morris MR, Gentle D, Winchester L, Bahn D, et al. (2009) CpG methylation profiling in VHL-related and VHL un-related renal cell carcinoma. Mol Cancer Res 7: 31.
21. Milani L, Landmark A, Kihlman A, Nordlund J, Haegsted T, et al. (2010) DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood 115: 1224–1225.
22. Sobhani I, Walker F, Roodt-Thorczal F, Abramowitz L, Johaneit H, et al. (2004) Anal carcinoma: incidence and effect of cumulative infections. AIDS 18: 1561–1569.
23. Grulich AE, Jin F, Conway EL, Stein AN, Hocking J (2010) Cancers attributable to human papillomavirus infection. Sex Health 7: 244–252.
24. Wong AK, Chai RC, Aggarwal N, Singh MK, Nichols WS, et al. (2010) Human papillomavirus genotypes in anal intraepithelial neoplasia and anal carcinoma as detected in tissue biopsies. Mod Pathol 23: 144–150.
25. Noffsinger A, Wurz M, Fenghui-Pfeifer CM (1992) The relationship of human papillomaviruses to anorectal neoplasia. Cancer 70: 1276–1287.
26. Fonger C, Frisch M, Jass JJ, Williams GT, Hilden J (2000) Anal cancer subtype reproducibility study. Virchows Arch 436: 229–233.
27. Arvey WB, Sweet MP, Alig GC, Arrick BA (1999) Methylation of Cpgs as a determinant of transcriptional activation at alternative promoters for transforming growth factor-beta3. Cancer Res 59: 2292–2296.
28. Nee M, Geoghegan JM, Munson P, Prabhu V, Liu Y, et al. (2000) Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratocytes. Cancer Res 60: 4289–4296.
29. Murvay M, Borbely AA, Konya J, Gergely L, Veress G (2004) Effect of human papillomavirus type 16 E6 and E7 oncogenes on the activity of the transforming growth factor-beta2 (TGF-beta2) promoter. Archives of virology 149: 2379–2392.
30. Cancu WG, Craven RJ, Bergman M, Xu L, Alitalo K, et al. (1994) Rak, a novel nuclear tyrosine kinase expressed in epithelial cells. Cell Growth Diff 5: 1347–1355.
57. Vogler M (2012) BCL2A1: the underdog in the BCL2 family. Cell death and differentiation 18: 186–195.
56. Illingworth RS, Gruenewald-Schneider U, Webb S, Kerr AR, James KD, et al. (2006) Overexpression of p53 target gene p21 in colon cancer. Cell death and differentiation 13: 1759–1767.
55. Civin CI, OConnor MJ, Emami B, Jackson DP, O’Connor TM, et al. (2002) p53-mediated apoptosis in human colorectal cancer cells. Cancer Res 62: 5580–5587.
54. Vos S, Zajac S, Sander M, Sauter G, Bruchhaus I, et al. (2002) The human DNA methyltransferase 1 gene is a p53 target gene. Cancer Res 62: 5286–5292.
53. Li P, Zou H, Wang Y, Wang Y, Li Y, et al. (2000) p53 expression and DNA methylation of the TP53 promoter in human colorectal carcinomas. Int J Cancer 87: 275–280.
52. Strathdee G, Holyoake TL, Sim A, Parker A, Oscier DG, et al. (2007) DNA methylation of the p21 gene is associated with the telomerase activity in chronic myeloid leukemia cells. Leukemia 21: 1390–1398.
51. Kuzmin I, Liu L, Dammann R, Geil L, Stanbridge EJ, et al. (2003) Inactivation of the mouse homolog of the human BCL2A1 gene in the human promyelocytic leukemia cell line NB4. Leukemia 17: 2008–2013.
50. Pratt ZL, Zhang J, Sugden B (2012) The latent membrane protein 1 (LMP1) oncogene of Epstein-Barr virus can simultaneously induce and inhibit apoptosis in B cells. Journal of virology 86: 4330–4339.
49. Sharma PL, Chaudhari H, Ware J, Mindley R, Rimland D (2012) Replication-independent expression of anti-apoptotic marker genes in human peripheral blood mononuclear cells infected with the wild-type HIV-1 and reverse transcriptase variants. Viral immunology 25: 12–20.
48. Iliopoulos D, Oikonomou P, Messinis I, Tsezou A (2009) Correlation of DNA methylation and apoptosis in hematopoietic cells. Apoptosis 11: 183–196.
47. Yu WP, Scott SA, Dong WF (2008) Induction of ID1 expression and apoptosis by the histone deacetylase inhibitor (trichostatin A) in human acute myeloid leukemia cells. Cell proliferation 41: 86–97.
46. Shivapurkar N, Toyoooka S, Pyo YT, Reddy J, Miyajima K, et al. (2004) DNA methylation regulates expression of the progesterone receptor. J Biol Chem 279: 26551–26556.
45. Byers LA, Deaton SL, Alder JK, Winnepenninckx V, Casero RA, et al. (2010) DNA methylation and Anal Squamous Neoplasia.
83. Gordon-Alonso M, Yanez-Mo M, Barreiro O, Alvarez S, Munoz-Fernandez MA, et al. (2006) Tetraspanins CD9 and CD81 modulate HIV-1-induced membrane fusion. J Immunol 177: 5129–5137.
84. Zhang S, Kodys K, Babcock GJ, Szabo G (2012) CD81/CD9 tetraspanins aid plasmacytoid dendritic cells in recognition of HCV-infected cells and induction of IFNalpha. Hepatology [Epub ahead of print].
85. Hernandez A (2005) Structure and function of the type 3 deiodinase gene. Thyroid 15: 665–674.
86. Martin-Suhero JJ, Ammertpolh O, Bibikova M, Wickham-Garcia E, Aguirre X, et al. (2009) A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One 4: e6986.
87. Huang MP, Rodgers KA, O’Mara R, Mehta M, Abuzahra HS, et al. (2011) The thyroid hormone degrading type 3 deiodinase is the primary deiodinase active in murine epidermis. Thyroid 21: 1263–1268.
88. Wong M, Fish EN (1998) RANTES and MIP-1alpha activate stats in T cells. J Biol Chem 273: 309–314.
89. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, et al. (1995) Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270: 1811–1815.
90. Cook DN, Beck MA, Collman TM, Kirby SL, Sheridan JF, et al. (1995) Requirement of MIP-1 alpha for an inflammatory response to viral infection. Science 269: 1583–1585.
91. Olschlagler P, Quetting M, Alvarez G, Durst M, Gissmann L, et al. (2009) Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants. Int J Cancer 125: 189–198.
92. Chen LM, Verity NJ, Chai KX (2009) Loss of prostasin (PRSS8) in human bladder transitional cell carcinoma cell lines is associated with epithelial-mesenchymal transition (EMT). BMC cancer 9: 377.
93. Leywarz C, Charles RP, Rubera I, Guitard M, Rotman S, et al. (2005) The epidermal barrier function is dependent on the serine protease CAP1/Prss1. The Journal of cell biology 170: 487–496.
94. Duenas-Gonzalez A, Lizano M, Candelaria M, Cetina L, Arce C, et al. (2005) Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer 4: 38.
95. Feng Q, Balasubramanian A, Hawes SE, Tourre P, Sow PS, et al. (2005) Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst 97: 273–282.
96. Fiatley JE, McNeil K, Balasubramani L, Tidy J, Stuart EL, et al. (2009) Folate status and aberrant DNA methylation are associated with HPV infection and cervical pathogenesis. Cancer Epidemiol Biomarkers Prev 18: 2782–2789.
97. Yang N, Nijhuis ER, Volders HH, Epink JJ, Lendvai A, et al. (2010) Gene promoter methylation patterns throughout the process of cervical carcinogenesis. Cell Oncol 32: 131–143.
98. Kim JH, Chou YD, Lee JS, Lee JH, Nam JH, et al. (2010) Assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens. Gynecol Oncol 116: 99–104.
99. Laurson J, Khan S, Chung R, Gross K, Raj K (2010) Epigenetic repression of E-cadherin by human papillomavirus 16 E7 protein. Carcinogenesis 31: 918–926.
100. Lin TS, Lee H, Chen RA, Ho ML, Lin CY, et al. (2003) An association of DNMT3b protein expression with PI6INK4a promoter hypermethylation in non-smoking female lung cancer with human papillomavirus infection. Cancer Lett 226: 77–84.
101. Kraus I, Drirsch C, Vinokurova S, Hovig E, Schneider A, et al. (2008) The majority of viral-cellular fusion transcripts in cervical carcinomas transcript cellular sequences of known or predicted genes. Cancer Res 68: 2514–2522.
102. Matovina M, Sabol I, Grubisic G, Gasperov NM, Grce M (2009) Identification of human papillomavirus type 16 integration sites in high-grade precancerous cervical lesions. Gynecol Oncol 113: 128–127.
103. Peter M, Rosty C, Couturier J, Radivoy F, Teshima H, et al. (2006) MYC activation associated with the integration of HPV DNA at the MYC locus in genital tumors. Oncogene 25: 5985–5993.
104. Wentezen N, Vinokurova S, von Knebel Doeberitz M (2004) Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 64: 3878–3884.
105. Yu T, Ferber MJ, Cheung TH, Chung TK, Wong YF, et al. (2005) The role of viral integration in the development of cervical cancer. Cancer Genet Cytogenet 158: 27–34.